The purpose of this 20-week randomized double-blind study in patients with resistant hypertension (rHTN) is to evaluate the efficacy, safety, and tolerability, of different doses of XXB750 administered as subcutaneous (SC) injections, compared to placebo. Since all study participants will be patients with rHTN, all study treatments will be given on top of maximally tolerated background antihypertensive therapy recommended by international guidelines for treatment of HTN (i.e., a thiazide or a thiazide-like diuretic, an angiotensin converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB), and a long-acting dihydropyridine calcium channel blocker (CCB).
0 Primary · 3 Secondary · Reporting Duration: 12 weeks
170 Total Participants · 5 Treatment Groups
Primary Treatment: Dose 3 · Has Placebo Group · Phase 2
Age 18+ · All Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: